drugset
drugset / Trial / NCT05011487

Neoadjuvant Osimertinib + Chemotherapy for EGFR-mutant Stage III NSCLC

NCT05011487 ↗

Phase 2 Recruiting 30 enrolled Sun Yat-sen University
NaSingle-groupOpen-labelTreatment

Summary

This is a phase II, single-arm, multi-center study of neoadjuvant osimertinib in combination with chemotherapy for the treatment of patients with resectable EGFR-mutant stage III (N2) non-squamous non-small cell lung cancer

Timeline

Start
2021-08-13
Primary completion
2023-09-01
Completion
2028-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Cisplatin Other / unclassified 75 mg/m2 —
Subject Osimertinib Small molecule 80 mg Oral
Subject Pemetrexed Small molecule 500 mg/m2 —

Indications

non-small cell lung carcinoma